NDAORALCAPSULEPriority Review
Approved
Nov 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
COMETRIQ (cabozantinib) by Exelixis is and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of ret, met, vegfr-1, -2 and -3, kit, trkb, flt-3, axl, ros1, tyro3, mer, and tie-2. Approved for renal cell carcinoma, hepatocellular carcinoma, medullary thyroid cancer. First approved in 2012.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMETRIQ (cabozantinib) is an oral multi-targeted tyrosine kinase inhibitor approved for metastatic medullary thyroid cancer. It inhibits RET, MET, VEGFR, KIT, and multiple other kinases involved in oncogenesis and tumor progression. The drug addresses a rare but serious indication with limited treatment alternatives.
$0.003BPart D
Peak5.8 years to LOEPeak-stage product with modest Part D utilization reflects niche indication; commercial team focuses on oncology specialist engagement rather than volume growth.
Mechanism of Action
and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis,…
Indications (3)
Worked on COMETRIQ at Exelixis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.